HGH vs Peptides: Recombinant Growth Hormone Compared With GH Secretagogue Peptides

The phrase HGH vs peptides hides a category error that is worth clearing up first, because growth hormone is itself a peptide. Somatropin, the recombinant form of human growth hormone, is a single polypeptide chain of 191 amino acids whose sequence is identical to the hormone produced by the anterior pituitary. It is a large molecule by peptide standards, which is why it is usually described as a protein drug rather than a peptide.

What people actually mean by the comparison is a contrast between hormone replacement and hormone stimulation. On one side sits recombinant human growth hormone, a prescription medicine delivered by subcutaneous injection, manufactured to pharmacopoeial standards and regulated as a biologic. On the other sits a family of much smaller molecules, generally 5 to 44 amino acids long, collectively called growth hormone secretagogues, which do not contain any growth hormone at all. They act on receptors in the hypothalamic-pituitary axis and ask the gland to release more of what it already makes.

The secretagogue family splits into two pharmacological subgroups. The first comprises GHRH analogues, which copy growth hormone-releasing hormone: sermorelin is the natural 1-29 fragment of GHRH, CJC-1295 is a modified analogue engineered for a longer circulating life, and tesamorelin is a full-length 44-amino-acid GHRH analogue with a stabilising modification. The second comprises ghrelin receptor agonists, which act at GHS-R1a rather than the GHRH receptor: ipamorelin and GHRP-6 belong here.

One compound frequently grouped with these peptides does not belong to them chemically. MK-677 (ibutamoren) is an orally active, non-peptide small molecule that also activates the ghrelin receptor. It is included in this discussion because its two-year clinical trial is the longest controlled dataset in the secretagogue space, but it should not be described as a peptide.

This page compares those two strategies only. It does not address muscle-building intentions or protocols; readers interested in how peptides are discussed in a training context will find that subject handled separately in our overview of peptides and bodybuilding.

Growth hormone is not secreted at a steady rate. The pituitary releases it in discrete bursts, with the largest pulses occurring during slow-wave sleep, separated by troughs in which circulating concentrations fall close to the detection limit. This pulsatile architecture is governed by two opposing hypothalamic signals: growth hormone-releasing hormone, which drives secretion, and somatostatin, which restrains it. Much of the biological signalling downstream of growth hormone appears to depend not only on how much hormone is released but on the pattern in which it arrives at the liver and other tissues.

Injected somatropin overrides this system. It introduces exogenous hormone into the circulation on a pharmacokinetic schedule set by the injection, not by the hypothalamus, producing a profile that does not reproduce physiological pulsatility. Because the hormone is supplied from outside, the pituitary becomes irrelevant to the result: somatropin works just as well in someone whose gland has been destroyed by surgery, radiotherapy or a tumour. That independence is precisely why it is the reference therapy for diagnosed deficiency, and it is also why negative feedback through IGF-1 and somatostatin can suppress whatever endogenous secretion remains.

Secretagogues work the other way around. A GHRH analogue such as sermorelin or tesamorelin binds the pituitary GHRH receptor and amplifies the bursts the gland is already attempting, which in principle preserves the pulsatile shape of secretion and leaves the IGF-1 feedback loop intact. A ghrelin receptor agonist such as ipamorelin or GHRP-6 works through a separate pathway that both stimulates somatotroph secretion and reduces somatostatin tone. The two mechanisms are complementary, which is the pharmacological rationale behind combining a GHRH analogue with a ghrelin receptor agonist in research settings.

The practical consequence of this upstream action is a ceiling effect. A secretagogue cannot release hormone that the pituitary cannot produce, cannot work in the absence of functioning somatotrophs, and cannot escape the negative feedback that rising IGF-1 imposes. Replacement therapy has no such ceiling, which explains both its clinical utility in true deficiency and its potential for supraphysiological exposure when misused.

A further difference concerns duration. Native GHRH and sermorelin are cleared within minutes. CJC-1295 was engineered with a drug affinity complex that binds serum albumin, extending its presence in circulation from minutes to days, and in healthy adults its estimated half-life was 5.8 to 8.1 days (Teichman et al., 2006). That shift from a brief pulse to a sustained signal is a meaningful pharmacological change, because a stimulus that never switches off no longer mimics physiology in the way a short-acting analogue does.

This is where the two families diverge most sharply, and it is the single most important thing for a reader to understand. Somatropin is an approved medicine in the United States, the European Union and most other regulated markets, for a defined and relatively narrow list of conditions. In adults the central indication is growth hormone deficiency confirmed by appropriate provocative testing, typically arising from pituitary or hypothalamic disease, surgery, radiotherapy or trauma. The Endocrine Society clinical practice guideline on adult growth hormone deficiency sets out how that diagnosis should be established before any replacement therapy is considered (Molitch et al., 2011). Paediatric indications are separate and include growth failure from several specific causes.

Crucially, ageing is not an approved indication. The age-related decline in growth hormone secretion, sometimes marketed as somatopause, is not recognised as a deficiency state requiring replacement, and guideline bodies have consistently declined to endorse treating it.

Among the secretagogues, the regulatory picture is thinner. Tesamorelin is the one clear exception: the FDA approved it in November 2010 under the brand name Egrifta for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. That approval is narrow and comes with an explicit limitation of use stating that long-term cardiovascular benefit and safety have not been studied. It is not an approval for body composition change in the general population.

Sermorelin occupies an unusual middle position. A branded sermorelin product, Geref, was approved in the United States in the 1990s, including for diagnostic assessment of pituitary growth hormone secretory capacity. The manufacturer discontinued it in 2008 for commercial rather than safety reasons and asked the FDA to withdraw the approvals. There is consequently no FDA-approved sermorelin product on the US market today, although it continues to be prepared by compounding pharmacies in some jurisdictions, which is a different legal status from an approved medicine.

CJC-1295, ipamorelin and GHRP-6 have never completed the development pathway to approval anywhere. They are investigational compounds, sold in most countries as research chemicals that are not approved for human use. Ipamorelin and CJC-1295 both reached clinical development and were discontinued. MK-677 likewise never obtained approval despite a substantial trial programme. None of them has a label, a regulated manufacturing standard for human administration, or an approved indication.

In genuine, biochemically confirmed growth hormone deficiency, the evidence base for replacement is substantial and spans decades. Controlled trials and long-term registry data in this population describe changes in body composition, bone density, lipid profile and quality-of-life measures, and the Endocrine Society guideline synthesises this literature into recommendations on who should be tested, how, and how replacement should be monitored (Molitch et al., 2011). The important qualifier is that this evidence is generated in people who lack the hormone. It does not transfer to people with normal pituitary function.

For that second population, the most informative synthesis remains the systematic review by Liu and colleagues, published in the Annals of Internal Medicine in 2008. The authors identified 44 articles describing 27 study samples, in which 303 healthy participants aged roughly 13 to 45 received growth hormone, representing 13.3 person-years of treatment. Their conclusion was blunt: the limited available evidence suggests growth hormone may alter body composition but has minimal effect on the athletic performance outcomes studied, and it may be associated with impaired exercise capacity. Participants receiving growth hormone more frequently experienced soft tissue edema and fatigue than those who did not.

That dissociation between appearance and function is one of the most consistently reproduced findings in the field. Lean mass as measured by imaging or bioimpedance can rise, in part because growth hormone promotes sodium and water retention, without a corresponding gain in strength or sprint capacity. Readers comparing growth hormone with anabolic agents on this basis may find the distinction developed further in our analysis of peptides versus steroids.

The other half of the somatropin evidence base concerns what happens when exposure exceeds physiological need. Sustained supraphysiological growth hormone produces a recognisable clinical picture familiar from acromegaly: arthralgia, myalgia, peripheral edema, carpal tunnel syndrome, insulin resistance and, over time, cardiac changes. These are not hypothetical risks inferred from mechanism. They are documented consequences of chronic growth hormone excess, which is why approved replacement is titrated against IGF-1 rather than given at a fixed amount.

Two structural advantages of somatropin should still be stated plainly. Its identity, purity and potency are guaranteed by pharmaceutical manufacturing and regulatory oversight, and its effects are predictable because they do not depend on residual pituitary capacity. Neither advantage is available for unapproved research peptides obtained outside the regulated supply chain.

The secretagogue evidence base is best read compound by compound, because the quality varies enormously and the compounds are often discussed as though they shared a single dataset. They do not.

Tesamorelin has the strongest human evidence by a wide margin. In the pivotal trial published by Falutz and colleagues in the New England Journal of Medicine in 2007, 412 patients with HIV and abdominal fat accumulation, 86% of them men, were randomised to subcutaneous tesamorelin or placebo over 26 weeks, with the primary endpoint being the percentage change in visceral adipose tissue on computed tomography. Visceral adipose tissue fell by 15.2% in the tesamorelin group while rising 5.0% on placebo, and lipid parameters improved. A later randomised trial by Stanley and colleagues in JAMA in 2014, in 50 antiretroviral-treated adults with abdominal fat accumulation, found a modest but statistically significant reduction in liver fat over six months, with the liver fat change correlating with the reduction in visceral adipose tissue.

CJC-1295 has published human pharmacology but no efficacy outcomes. Teichman and colleagues reported two randomised, placebo-controlled, double-blind ascending studies in healthy adults aged 21 to 61 (JCEM, 2006). A single subcutaneous administration raised mean plasma growth hormone 2-fold to 10-fold for six days or more and mean plasma IGF-1 1.5-fold to 3-fold for 9 to 11 days, with an estimated half-life of 5.8 to 8.1 days. After repeated administration, mean IGF-1 remained above baseline for up to 28 days. The compound was described as safe and relatively well tolerated in that short-term setting. What does not exist is any trial showing that this biochemical change improves a clinical outcome. Readers looking for preparation arithmetic rather than pharmacology should use the dedicated CJC-1295 calculator, which covers that question directly.

Ipamorelin is supported chiefly by its original characterisation paper. Raun and colleagues described it in the European Journal of Endocrinology in 1998 as a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) and the first ghrelin receptor agonist with a selectivity for growth hormone release comparable to that of GHRH. In their experiments it did not release ACTH or cortisol at levels significantly different from GHRH stimulation, even at amounts more than 200-fold above the ED50 for growth hormone release. This selectivity claim, which is the single most repeated statement about ipamorelin, comes from preclinical work, not from controlled human trials of repeated administration.

GHRP-6 is the oldest of the group and the one whose human data are most clearly limited to single sessions. Ilson and colleagues reported in JCEM in 1989 that the hexapeptide selectively stimulated growth hormone release in healthy human subjects without comparable effects on other pituitary hormones. A later overnight study in normal men by Frieboes and colleagues (Neuroendocrinology, 1995) compared repeated intravenous GHRP-6 boluses with placebo and found increases in growth hormone, ACTH and cortisol secretion along with increased stage 2 sleep, while slow-wave sleep did not increase. GHRP-6 is also well known for marked appetite stimulation through the ghrelin pathway. There is no controlled trial of repeated GHRP-6 administration over weeks or months for any outcome.

MK-677 (ibutamoren), the non-peptide in the group, provides the longest controlled follow-up. Nass and colleagues conducted a two-year double-blind, randomised, placebo-controlled modified-crossover trial in healthy older adults (Annals of Internal Medicine, 2008). Daily oral administration restored growth hormone and IGF-1 to levels seen in healthy young adults, and fat-free mass increased while it declined on placebo. Body weight rose 2.7 kg in the MK-677 group versus 0.8 kg on placebo. The trial also reported the metabolic cost: fasting blood glucose increased by an average of 0.3 mmol/L (5 mg/dL) and insulin sensitivity decreased. The accompanying editorial in the same issue concluded that growth hormone secretagogues were not yet ready for use against the effects of ageing.

A 2018 review by Sigalos and Pastuszak in Sexual Medicine Reviews surveyed this literature and reached a consistent conclusion: secretagogues reliably raise growth hormone and IGF-1, but the clinical outcome data, and particularly the long-term safety data, remain insufficient to support routine use.

The table below summarises the structural differences discussed above. It is a comparison of pharmacological and regulatory characteristics only, and contains no guidance on use.

Read as a whole, the table shows that the two families are not interchangeable options addressing the same question. Somatropin is a treatment for a diagnosed disease. The secretagogues, with the single exception of tesamorelin in its labelled population, are investigational tools whose biochemical activity is better documented than their clinical value.

Medical disclaimer: this comparison is provided for educational purposes only. It is not medical advice, does not constitute a recommendation to use any of these compounds, and should not be used to self-diagnose or self-treat. Anyone considering growth hormone axis therapy should consult a qualified endocrinologist.

For somatropin, the adverse effect profile is well mapped because the compound has been studied and marketed for decades. The commonest issues in therapeutic use relate to fluid retention and tissue growth: peripheral edema, arthralgia and myalgia, paraesthesia and carpal tunnel syndrome. Growth hormone also antagonises insulin action, so impaired glucose tolerance and new-onset or worsened diabetes are recognised risks requiring monitoring. In the systematic review of healthy young participants, soft tissue edema and fatigue were the adverse effects reported more often in growth hormone recipients than in controls (Liu et al., 2008).

With sustained supraphysiological exposure, the concern widens to the acromegaly-like syndrome described earlier: soft tissue and bony overgrowth, cardiomyopathy, hypertension and sleep apnoea. Because growth hormone acts largely through IGF-1, a mitogenic signal, there is also a long-standing theoretical concern about proliferative disease, which is one reason approved replacement is contraindicated in active malignancy and is monitored against IGF-1 rather than given open-endedly.

The secretagogues carry a different and in several respects less well characterised risk profile. Because their action is capped by pituitary capacity and intact negative feedback, the ceiling for IGF-1 elevation should in principle be lower than with injected hormone. That argument is mechanistically reasonable but it has not been demonstrated through long-term safety studies, and the ceiling does not apply uniformly: a long-acting GHRH analogue that keeps IGF-1 elevated for weeks changes the exposure profile considerably.

Compound-specific concerns matter here. GHRP-6 is not selective: the overnight study by Frieboes and colleagues found increased ACTH and cortisol secretion alongside growth hormone, and the compound produces pronounced hunger through ghrelin receptor activation. Whether repeated administration causes clinically meaningful cortisol elevation has never been tested in humans. Ipamorelin was specifically designed to avoid this, and the selectivity data in the original characterisation are genuinely favourable, but they are preclinical. MK-677 provides the clearest long-term warning signal, since the two-year trial documented an average fasting glucose rise of 0.3 mmol/L and reduced insulin sensitivity.

Finally there is a risk category that has nothing to do with pharmacology. Approved somatropin and tesamorelin come from regulated manufacturing. Unapproved research peptides do not, and purity, identity, sterility and endotoxin content are not assured by any human-use standard. The FDA has issued warning letters to firms marketing unapproved peptide products. For a compound injected subcutaneously, that quality gap is a material safety issue in its own right, independent of whatever the molecule does once in the body.

Growth hormone itself is a poor analyte to measure. Its secretion is pulsatile and strongly circadian, so a single blood sample may catch a peak or a trough with no way to tell which, and its circulating half-life is on the order of minutes. A normal result and a severely abnormal result can come from the same person hours apart. This is why the diagnosis of adult growth hormone deficiency relies on provocative stimulation testing rather than a resting measurement, as set out in the Endocrine Society guideline (Molitch et al., 2011).

Insulin-like growth factor 1 solves most of these problems. IGF-1 is produced mainly by the liver in response to growth hormone, circulates bound to IGF-binding proteins that greatly extend its half-life, and shows little pulsatility. A single IGF-1 measurement therefore reflects integrated growth hormone exposure over roughly the preceding days rather than the minute of sampling. That stability is what makes it usable as a titration target in approved therapy and as a safety boundary: keeping IGF-1 within an age-adjusted and sex-adjusted reference range is the practical way clinicians avoid the acromegaly-like consequences of excess.

IGF-1 is equally central to the secretagogue literature, and for the same reason. The Teichman study of CJC-1295 reported IGF-1 as a primary read-out precisely because its 9-to-11-day elevation after a single administration could be measured reliably, whereas tracking the underlying growth hormone pulses would have required intensive sampling. The two-year MK-677 trial likewise used IGF-1 restoration to young-adult levels as its key pharmacodynamic endpoint.

In anti-doping, the logic is inverted but the marker is the same. Recombinant growth hormone is nearly identical to the endogenous hormone and clears quickly, so direct detection has a very short window. Anti-doping science therefore developed an indirect biomarker approach built on growth hormone-dependent markers: IGF-1 together with procollagen type III amino-terminal propeptide (P-III-NP), combined into a discriminant score. The two markers have different kinetics, with IGF-1 rising within a couple of weeks of administration and falling back quickly after cessation, while P-III-NP rises more gradually and returns to normal more slowly, which is what makes the combination informative over a longer window than either alone.

One consequence follows directly for anyone subject to testing. Because the biomarker approach detects the downstream consequence of growth hormone exposure rather than the administered molecule, a secretagogue that successfully raises IGF-1 is not invisible to it. Stimulating the pituitary instead of injecting hormone changes the mechanism, not the biochemical footprint.

The legal positions of the two families are genuinely different, and conflating them is a common error. Somatropin is a prescription medicine, legal to possess and use when prescribed for an approved indication and dispensed through a pharmacy. In many jurisdictions it is additionally controlled: in the United States, human growth hormone distribution for non-approved uses is subject to specific federal criminal provisions, which is a stricter position than applies to most prescription drugs. Obtaining or supplying it outside the medical system is therefore not a regulatory technicality.

Tesamorelin is likewise a prescription medicine within its labelled HIV lipodystrophy indication. Sermorelin sits in a compounding grey zone that varies substantially between countries, since there is no approved product on the US market but pharmacy-compounded preparations exist in some settings. CJC-1295, ipamorelin, GHRP-6 and MK-677 are, in most jurisdictions, neither approved medicines nor legal dietary ingredients. They are sold as research chemicals that are explicitly not approved for human use, and in some countries their supply for human consumption is unlawful. Legal status should always be verified locally rather than assumed from a vendor's website.

The anti-doping position, by contrast, is uniform and leaves no ambiguity. Both families fall under category S2 of the World Anti-Doping Agency Prohibited List, covering peptide hormones, growth factors, related substances and mimetics. Growth hormone and its analogues and fragments are addressed in S2.2.3. Growth hormone releasing factors are addressed in S2.2.4, which covers GHRH and its analogues, growth hormone secretagogues and their mimetics, and the GH-releasing peptides. Sermorelin, CJC-1295, tesamorelin, ipamorelin, ibutamoren (MK-677) and the GHRPs are among the substances named or captured there.

Two features of this classification deserve emphasis. First, S2 substances are prohibited at all times, both in competition and out of competition, so there is no permitted period of use. Second, the list is non-exhaustive: substances with similar chemical structure or biological effect are prohibited whether or not they appear by name, which closes the loophole that novel analogues might otherwise open. A therapeutic use exemption is possible in principle for a documented medical condition, but it requires formal approval before use, not retrospective justification.

Athletes, military personnel and anyone else subject to testing should treat every compound discussed on this page as banned. A prescription does not change that status by itself, and the fact that a compound is marketed as a natural stimulator of one's own hormone has no bearing on its prohibited classification.

Reminder: this article is educational and does not recommend use of any compound described. Several of the peptides discussed are research compounds that are not approved for human use. Consult a qualified healthcare professional before considering any intervention affecting the growth hormone axis, and verify the legal status in your own country.